| Nivolumab for recurrent squamous-cell carcinoma of the head and neck RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... New England Journal of Medicine 375 (19), 1856-1867, 2016 | 4544 | 2016 |
| Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by … RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... Oral oncology 81, 45-51, 2018 | 724 | 2018 |
| Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma E Saâda-Bouzid, C Defaucheux, A Karabajakian, VP Coloma, V Servois, ... Annals of Oncology 28 (7), 1605-1611, 2017 | 585 | 2017 |
| Blood diffusion and Th1-suppressive effects of galectin-9–containing exosomes released by Epstein-Barr virus–infected nasopharyngeal carcinoma cells J Klibi, T Niki, A Riedel, C Pioche-Durieu, S Souquere, E Rubinstein, ... Blood, The Journal of the American Society of Hematology 113 (9), 1957-1966, 2009 | 487 | 2009 |
| Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum … JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ... The Lancet Oncology 16 (5), 583-594, 2015 | 460* | 2015 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 399 | 2017 |
| Are G3 ENETS neuroendocrine neoplasms heterogeneous? FL Vélayoudom-Céphise, P Duvillard, L Foucan, J Hadoux, CN Chougnet, ... Endocrine-related cancer 20 (5), 649-657, 2013 | 366 | 2013 |
| Treatment de‐escalation in HPV‐positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives H Mirghani, F Amen, P Blanchard, F Moreau, J Guigay, DM Hartl, ... International journal of cancer 136 (7), 1494-1503, 2015 | 267 | 2015 |
| Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells D Mrizak, N Martin, C Barjon, AS Jimenez-Pailhes, R Mustapha, T Niki, ... Journal of the National Cancer Institute 107 (1), dju363, 2015 | 207 | 2015 |
| Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01 JPH Machiels, S Henry, S Zanetta, MC Kaminsky, N Michoux, D Rommel, ... Journal of Clinical Oncology 28 (1), 21-28, 2010 | 186 | 2010 |
| A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02) M Frikha, A Auperin, Y Tao, F Elloumi, N Toumi, P Blanchard, P Lang, ... Annals of Oncology 29 (3), 731-736, 2018 | 167 | 2018 |
| Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study J Guigay, J Fayette, AF Dillies, C Sire, JN Kerger, I Tennevet, JP Machiels, ... Annals of Oncology 26 (9), 1941-1947, 2015 | 159 | 2015 |
| Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells C Gourzones, A Gelin, I Bombik, J Klibi, B Vérillaud, J Guigay, P Lang, ... Virology journal 7, 1-12, 2010 | 157 | 2010 |
| Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma J Hadoux, D Malka, D Planchard, JY Scoazec, C Caramella, J Guigay, ... Endocrine-related cancer 22 (3), 289-298, 2015 | 156 | 2015 |
| Human papilloma virus testing in oropharyngeal squamous cell carcinoma: what the clinician should know H Mirghani, F Amen, F Moreau, J Guigay, M Ferchiou, AE Melkane, ... Oral oncology 50 (1), 1-9, 2014 | 141 | 2014 |
| Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use RL Ferris, L Licitra, J Fayette, C Even, G Blumenschein Jr, KJ Harrington, ... Clinical Cancer Research 25 (17), 5221-5230, 2019 | 138 | 2019 |
| Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck K Saleh, A Daste, N Martin, E Pons-Tostivint, A Auperin, ... European Journal of Cancer 121, 123-129, 2019 | 130 | 2019 |
| Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell … J Guigay, A Aupérin, J Fayette, E Saada-Bouzid, C Lafond, M Taberna, ... The Lancet Oncology 22 (4), 463-475, 2021 | 124 | 2021 |
| Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma C Durante, H Boukheris, C Dromain, P Duvillard, S Leboulleux, D Elias, ... Endocrine-related cancer 16 (2), 585-597, 2009 | 120 | 2009 |
| Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (≥10%) Well-Differentiated … R Abgral, S Leboulleux, D Deandreis, A Auperin, J Lumbroso, C Dromain, ... The Journal of Clinical Endocrinology & Metabolism 96 (3), 665-671, 2011 | 114 | 2011 |
